Provided are devices and related methods for weight loss. A size-varying gastric balloon having a passage connected to an elongated sleeve forms a continuous pathway extension so that swallowed food is not absorbed by the body, thereby promoting weight loss. The connection of the sleeve to the gastric balloon avoids the need to directly anchor the proximal sleeve, with the balloon providing that anchoring function. Also provided are gastric balloons having a shape-controllable funnel to provide desired weight loss parameters tailored to the need of an individual and specially configured double lumen sleeves to facilitate controlled nutrition supply to a patient. Methods of deploying any of the devices described herein for weight-loss are also provided.

A device for treating obesity of a patient, the device comprising: at least one operable stretching device implantable in the patient and adapted to stretch a portion of the patient's stomach wall, and an implantable control unit for automatically controlling the operable stretching device, when the control unit and stretching device are implanted, to stretch the stomach wall portion in connection with the patient eating such that satiety is created.

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may provide slowed entry into the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Some devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. The implants are formed of materials that permit the implant to be compressed into a substantially linear transoral delivery configuration and that will resist degradation over a period of at least six months within the stomach.

The present disclosure provides an inflatable weight control device that is implanted long-term with an endoscope in obese and bariatric human patients to promote early and prolonged satiety. The device includes a flexible, inflatable member coupled to a valve body assembly and an elongated durable module residing within the flexible member. The flexible member is selectively inflated to form two bulbs with a central passageway extending through the bulbs and the valve body assembly. Once the bulbs are inflated, the device is retained within the patient's pyloric valve to form a gastric outlet obstruction wherein chyme accumulates and then is directed through the central passageway to reach the patient's duodenum. Due to its unique configuration, the implanted device reduces gastric outflow which results in early and prolonged satiety when the patient consumes normal-sized meals or food portions, thereby reducing food consumption and increasing the patient's weight loss.

An apparatus for the treatment of acid reflux disease has an implantable movement restriction device adapted to be at least partly invaginated by a patient's stomach fundus wall. A substantial part of the outer surface of the movement restriction device is adapted to rest against the stomach wall without injuring the latter in a position between the patient's diaphragm and at least a portion of the lower part of the invaginated stomach fundus wall, such that movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is restricted, to thereby prevent the cardia from sliding through the patient's diaphragm opening into the patient's thorax, so as to maintain the supporting pressure against the patient's cardia sphincter muscle exerted from the patient's abdomen. The movement restriction device has a size of at least 125 mm.sup.3 and a circumference of at least 15 mm.

An intraluminar method of treating a reflux disease in a patient by implanting a device comprising a non-encircling implantable movement restriction device that, when implanted in a patient, restricts the movement of the cardiac notch in relation to the diaphragm muscle, preventing the cardia from sliding through the esophageal hiatus. The intraluminar method comprises introducing an instrument through the esophagus and into the stomach of the patient, introducing the non-encircling implantable movement restriction device through the esophagus using said instrument, affixing the non-encircling movement restriction device to the fundus wall, such that it does not encircle the esophagus or stomach, thereby preventing the cardia from sliding through the esophageal hiatus and thus reducing reflux disease without encircling the esophagus or stomach.

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, certain devices slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. A number of devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse.

Transoral implantable devices includes an inflatable body made of a material that permits it to be compressed into a substantially linear transoral delivery configuration and that when implanted in the stomach is adapted to reduce obesity or weight by stimulating the stomach walls of the patient. The body has a plurality of popout features on its surface that reside generally flush with the inflatable body in relaxed, refracted states, and which respond to an increase in pressure within the inflatable body by projecting outward from the body in a stressed, deployed state. The popout features may convert between their retracted and deployed states by movement of rolling diaphragms formed in the inflatable body.

A biocompatible implant for a method of treating a reflux disease in a patient by preventing the cardia sphincter from sliding through the patient's diaphragm hiatus opening into the patient's thorax, so as to maintain a pressure support from the patient's abdomen that supports the patient's cardia sphincter. The biocompatible implant has a rigid shape, a circumference of at least 15 mm and is configured to be introduced into the patient's abdomen through a trocar, be fully invaginatable in the patient's fundus wall, and function as an implantable movement restricting device preventing the cardia sphincter from sliding through the patient's diaphragm, when implanted.

The invention relates surgical abdominal methods of treating obesity in a patient by implanting a volume filling device that, when implanted in a patient, reduces the food cavity in size by a volume substantially exceeding the volume of the volume filling device. Also disclosed is a laparoscopic instrument for providing a volume filling device to be invaginated in the stomach wall of a human patient to treat obesity.